医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
14期
8-8
,共1页
癌%非小细胞肺癌%放射治疗%大分割%后程加速超分割
癌%非小細胞肺癌%放射治療%大分割%後程加速超分割
암%비소세포폐암%방사치료%대분할%후정가속초분할
carcinoma%non smal cel lung cancer%radiotherapy%high segmentation%late course accelerated hyperfractionation
目的：探讨大分割联合后程加速超分割放射治疗非小细胞肺癌临床疗效。方法：选择我院2008年1月～2013年12月收治的非小细胞肺癌患者100例，将患者随机分为大分割联合后程加速超分割放疗组(治疗组)和常规分割放疗组(对照组)，每组50例，观察两组患者临床疗效，并进行分析比较。结果：治疗后加速组病人的有效率为88.0％（44/50），而对照组为66.0％（17/50），两组比较有显著差异（P＜0.05)；两组病人急性放射反应的差别无统计学意义（P＞0.05）。结论：大分割放疗联合后程加速超分割放疗可提高非小细胞肺癌的近期疗效，未增加毒副反应，耐受性良好，远期疗效及晚期反应仍需进一步观察。
目的：探討大分割聯閤後程加速超分割放射治療非小細胞肺癌臨床療效。方法：選擇我院2008年1月～2013年12月收治的非小細胞肺癌患者100例，將患者隨機分為大分割聯閤後程加速超分割放療組(治療組)和常規分割放療組(對照組)，每組50例，觀察兩組患者臨床療效，併進行分析比較。結果：治療後加速組病人的有效率為88.0％（44/50），而對照組為66.0％（17/50），兩組比較有顯著差異（P＜0.05)；兩組病人急性放射反應的差彆無統計學意義（P＞0.05）。結論：大分割放療聯閤後程加速超分割放療可提高非小細胞肺癌的近期療效，未增加毒副反應，耐受性良好，遠期療效及晚期反應仍需進一步觀察。
목적：탐토대분할연합후정가속초분할방사치료비소세포폐암림상료효。방법：선택아원2008년1월～2013년12월수치적비소세포폐암환자100례，장환자수궤분위대분할연합후정가속초분할방료조(치료조)화상규분할방료조(대조조)，매조50례，관찰량조환자림상료효，병진행분석비교。결과：치료후가속조병인적유효솔위88.0％（44/50），이대조조위66.0％（17/50），량조비교유현저차이（P＜0.05)；량조병인급성방사반응적차별무통계학의의（P＞0.05）。결론：대분할방료연합후정가속초분할방료가제고비소세포폐암적근기료효，미증가독부반응，내수성량호，원기료효급만기반응잉수진일보관찰。
Objective:To investigate the high segmentation combined with late course accelerated hyperfractionated clinical efficacy of radiotherapy for non smal cel lung cancer. Methods: in our hospital from 2008 January to 2013 December were 100 cases of patients with non smal cel lung cancer,the patients were randomly divided into high segmentation combined with late course accelerated hyperfractionated radiotherapy group (treatment group) and conventional radiotherapy group (control group), 50 cases in each group, two groups of patients with clinical curative effect observation,comparison and analysis. Results:after the treatment group patients accelerated rate was 88% (44/50), while the control group was 66% (17/50),there was significant difference between two groups (P<0.05);two patients of acute radiation reactions without significant difference (P>0.05). Conclusion: hypofractionated radiotherapy combined with late course accelerated hyperfractionated radiotherapy can improve the therapeutic effect of non smal cel lung cancer, and has no toxic and side reaction increases, good endurance,long term outcomes and late reaction stil needs further observation.
